Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
66
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Gilead Sciences